We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-11.03%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$385M
AUM Growth
+$21.5M
Cap. Flow
+$281M
Cap. Flow %
73.04%
Top 10 Hldgs %
69.74%
Holding
41
New
10
Increased
16
Reduced
3
Closed
8

Top Buys

Rank Stock Value
1
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$22.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$15.9M
3
IBRX icon
ImmunityBio
IBRX
+$15.9M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$15M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$14.4M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$8.89M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$5.67M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$5.58M
4
FOLD
Amicus Therapeutics
FOLD
+$5.33M
5
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 89.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$59.5M 15.46%
4,250,199
-340,000
-7% -$5.33M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$50M 13%
1,453,055
+453,055
+45% +$13.7M
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$301M
$24M 6.23%
2,124,593
+685,900
+48% +$8.39M
NDRM
4
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$22.8M 5.93%
1,103,093
+731,982
+197% +$15M
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$22.4M 5.81%
804,299
+192,300
+31% +$6.06M
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.45B
$19.2M 5%
581,900
+86,900
+18% +$3.62M
PTX
7
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$19M 4.93%
600,456
+475,439
+380% +$22.7M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.03B
$18.3M 4.76%
3,180,913
+257,848
+9% +$2.01M
SRNE
9
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$18.1M 4.69%
2,151,437
-35,083
-2% -$559K
CASC
10
DELISTED
Cascadian Therapeutics, Inc.
CASC
$15.1M 3.92%
917,770
-18,397
-2% -$377K
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.64B
$15.1M 3.92%
+469,025
New +$15.9M
TLGT
12
DELISTED
Teligent, Inc
TLGT
$11.6M 3.03%
177,978
+2,610
+1% +$202K
AEGR
13
DELISTED
Aegerion Pharmaceuticals
AEGR
$11M 2.85%
+806,300
New +$14.4M
AGEN
14
Agenus
AGEN
$280M
$10.1M 2.63%
112,046
– –
DERM
15
DELISTED
Dermira, Inc.
DERM
$8.48M 2.2%
+363,250
New +$8.83M
SPPI
16
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$7.87M 2.05%
+1,315,600
New +$9.13M
IBRX icon
17
ImmunityBio
IBRX
$7.11B
$7.3M 1.9%
+728,887
New +$15.9M
INNL
18
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$6.29M 1.64%
502,422
+5,000
+1% +$68.9K
EGLT
19
DELISTED
Egalet Corporation
EGLT
$5.81M 1.51%
+440,606
New +$5.6M
SIOX
20
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.25M 1.37%
50,809
+8,309
+20% +$974K
IWM icon
21
PUT
iShares Russell 2000 ETF
IWM
$79.2B
$4.98M 1.29%
+1,280,000
New +$152M
VCYT icon
22
Veracyte
VCYT
$4.4B
$3.62M 0.94%
772,297
+13,800
+2% +$131K
TRIL
23
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.35M 0.87%
255,097
+160,697
+170% +$2.95M
FBIO icon
24
Fortress Biotech
FBIO
$111M
$3.32M 0.86%
85,035
+23,066
+37% +$1.08M
VCEL icon
25
Vericel Corp
VCEL
$2.34B
$3.08M 0.8%
1,135,120
+51,634
+5% +$170K
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Avoro Capital Advisors held 41 positions worth $385M, up 5.9% from $363M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors deployed $281M of net new capital in Q3 2015, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Sarepta Therapeutics: 469,025 shares worth $15.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $5.33M trimmed.

  • Avoro Capital Advisors's largest Q3 2015 buy was Sarepta Therapeutics: 469,025 shares worth $15.1M.
  • Avoro Capital Advisors added most to Pernix Therapeutics Holdings, Inc. in Q3 2015, an estimated $22.7M increase.
  • Avoro Capital Advisors's biggest Q3 2015 reduction was Amicus Therapeutics, cutting an estimated $5.33M.
  • Avoro Capital Advisors fully exited Celldex Therapeutics in Q3 2015, selling an estimated $8.89M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $385M portfolio in Q3 2015.
  • Avoro Capital Advisors opened 10 new positions and closed 8 in Q3 2015.
  • Avoro Capital Advisors's portfolio value rose 5.9% quarter-over-quarter to $385M.

Based on Avoro Capital Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.